Scientists and clinicians in the Barshop Institute for Longevity & Aging Studies and the Glenn Biggs Institute for Alzheimer's and Neurodegernerative diseases are strengthening team science at UT Health San Antonio.
Barshop Institute has the national distinction of two NIA-funded centers, a testing site of the NIA-sponsored Interventions Testing Program, and U.S. Department of Veterans Affairs Geriatric Research, Education, and Clinical Center.
Sudha Seshadri, MD, founding director of the Biggs Institute and principal investigator of the National Institute of Aging Alzheimer's Disease Sequencing Project.
UT Health San Antonio partners with the San Antonio GRECC at the Audie L. Murphy Memorial VA Hospital to initiate clinical research trials to further advanced knowledge of age-related diseases and provide preventive solutions.
The Pepper and Shock grants, which total $11 million over the next five years, support basic research of the biology of aging and translation of discoveries into human application. The renewals further cement the Barshop Institute as one of America’s premier centers of aging research.
Although it’s not a cure for ALS, an oral drug slowed patients’ rate of functional decline in a clinical trial that included five patients at UT Health San Antonio. If the finding is repeated in larger trials, the drug could give families more time with their loved ones who have ALS.
An article published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association cites decades of published scientific evidence to make a compelling case for SARS-CoV-2’s expected long-term effects on the brain and nervous system.
In the war on cancer and other diseases including COVID-19, old drugs approved for other conditions are being studied for new purposes. It’s a strategy that will now be tested in Alzheimer’s disease with a drug called rapamycin.